Vaxcyte: Is the Big Vaccine Test Coming?
Vaxcyte: Is the Big Vaccine Test Coming?
is getting close to a major Phase 3 readout for VAX 31. VAX 31 is a vaccine for pneumococcal disease. The trial is called EXPAND. A strong result could make the vaccine a real competitor to older shots. It could also open the door to a bigger market. The company still needs to prove the vaccine is safe and works well. I’m watching this one closely because a clean result could really change how people see the stock.
The Phase 3 results could be a major catalyst for Vaxcyte, but expectations may already be reflected in the stock price. I’d be watching both the vaccine’s effectiveness and safety data before judging how much upside remains.
Totally agree with the sentiment here. Vaxcyte has been on my watchlist for a while, so I am definitely waiting for the data.
The Phase 3 readout could be a major catalyst, but safety, efficacy, and commercial potential will be key.
Good point, the commercial rollout will be just as tricky as the trial itself for Vaxcyte.